• Biogen's high dose nusinersen (SPINRAZA) regimen for spinal muscular atrophy has published new clinical results in Nature Medicine and is currently under FDA review.
• The FDA has granted Breakthrough Therapy Designation to litifilimab for cutaneous lupus erythematosus, highlighting another late stage program for the company.

For investors watching Biogen (NasdaqGS:BIIB), these two updates come at a time when the stock is trading around $201.18. The share price reflects a mixed track record, with a 42.3% return over the past year and longer term 3 year and 5 year returns of 29.7% and 27.6% declines respectively.

High dose nusinersen and litifilimab now sit among Biogen's more visible late stage assets, and regulatory decisions could influence how investors evaluate the portfolio mix. These developments may also shape sentiment around the company’s ability to advance new therapies in neurological and autoimmune conditions.

Stay updated on the most important news stories for Biogen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Biogen.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$201.18, Biogen trades about 2.3% above the US$196.57 analyst price target, sitting close to consensus.
• ✅ Simply Wall St Valuation: Simply Wall St flags the shares as trading roughly 46.2% below its estimated fair value.
• ✅ Recent Momentum: The 30 day return of about 7.6% suggests recent positive share price momentum around the news.

Check out Simply Wall St's in depth valuation analysis for Biogen.

Key Considerations

• 📊 The nusinersen and litifilimab updates strengthen Biogen's late stage pipeline, which can be important when you weigh its current valuation and earnings profile.
• 📊 Watch FDA decisions, future revenue and earnings trends, and how the P/E of 22.8 compares with the biotech industry average of 22.8.
• ⚠️ Simply Wall St highlights one minor risk related to large one off items affecting reported earnings, so underlying profit quality is worth checking against these trial headlines.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Biogen analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.